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Genetic variance of SGK-1 is associated with blood pressure,
blood pressure change over time and strength of the insulin-
diastolic blood pressure relationship.
Background. Insulin stimulation of the serum- and
glucocorticoid-regulated kinase 1 (SGK-1) prolongs the half-
life of the epithelial sodium channel, a protein which is essen-
tial for blood pressure regulation. The aim of this study was
to investigate if variation in the SGK-1 gene is associated with
increased blood pressure and strength of the insulin-blood pres-
sure relationship.
Methods. A promoter C/T, an intron 6 C/T and an exon 8 C/T
polymorphism in the SGK-1 gene were genotyped in 4830 sub-
jects from the Malmo¨ Diet and Cancer (MDC) material of
whom 4001 were free from antihypertensive medication. Of
these, 2171 subjects had also been investigated 11.2 ± 4.4 years
earlier in the Malmo¨ Preventive Project (MPP).
Results. In untreated MDC subjects, intron 6 CC genotype
carriers had higher diastolic blood pressure than carriers of the
T allele (P = 0.02) and exon 8 C allele carriers had higher systolic
blood pressure than TT genotype carriers (P = 0.05). Subjects
simultaneously carrying the intron 6 CC genotype and the exon
8 CC or CT genotype (SGK-1 risk) had higher systolic blood
pressure (P = 0.03) and higher diastolic blood pressure (P =
0.009) than noncarriers. From MPP to MDC, the percent change
in blood pressure per year was higher for systolic blood pressure
(P = 0.002) and diastolic blood pressure (P = 0.001) in SGK-1
risk carriers than noncarriers. The correlation between fasting
plasma insulin concentration and diastolic blood pressure was
stronger in SGK-1 risk carriers than in non-carriers (P = 0.04).
Conclusion. Our data suggest that SGK-1 risk carriers
are at increased risk of hypertension and are more sensi-
tive to the blood pressure elevating effects associated with
hyperinsulinemia.
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Blood pressure is a complex phenotype as indicated
by its normal distribution in the population, implicating
that blood pressure is influenced by several environmen-
tal and genetic factors. It has been suggested that between
30% and 60% of blood pressure variation in the popu-
lation is determined by genetic factors [1]. Both the en-
vironmental and genetic mechanisms that lead to blood
pressure elevation and subsequently to hypertension are
to large extents unknown. One strategy to unravel the
complex genetic background of population blood pres-
sure variation is to explore genes in which mutations are
known to cause monogenic forms of hypertension and
genes coding for key regulators of the proteins altered
in these forms of hypertension. A number of mutations
causing rare monogenic forms of hypertension have been
described, all of which impair the kidneys’ ability to ex-
crete sodium [2]. One monogenic form of hypertension
is Liddle’s syndrome [3]. This disease is caused by mu-
tations that delete or change a proline-rich segment of
either the b or c subunit of the amiloride-sensitive ep-
ithelial sodium channel (ENaC), rendering it refractory
to down-regulation by the ubiquitin ligase “neural pre-
cursor cell expressed, developmentally down-regulated
4 like” (NEDD4L) in the distal nephron [4, 5]. This re-
sults in constitutive renal hyperreabsorption of sodium
through the overexpressed ENaC, thereby leading to vol-
ume overload and hypertension. Although the ENaC
locus has been linked to blood pressure variation, no
specific genetic ENaC variants have been consistently
associated with population blood pressure variation or
primary hypertension [6–8]. Even though ENaC muta-
tions that affect blood pressure seem to be rare in the
population [6, 9], Liddle’s syndrome has taught us that
changes in ENaC expression or activity can strongly in-
fluence human blood pressure. In recent years the path-
ways through which ENaC and NEDD4L expression
and activity are regulated have begun to unravel. The
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Table 1. Clinical characteristics of blood pressure and hypertensive groups
MPP without AHT MDC without AHT MPP to MDC MDC with AHT
(N = 2171) (N = 4001) (N = 2171) (N = 829)
Age years 47.2 ± 5.7 57.4 ± 6.0 59.5 ± 5.5
Body mass index kg/m2 24.2 ± 3.2 25.7 ± 3.7 27.7 ± 4.3
Gender % male 54 41 45
Systolic blood pressure mm Hg 123 ± 13.2 140 ± 18.1 152 ± 19.2
Diastolic blood pressure mm Hg 81.9 ± 8.4 86.1 ± 9.0 92.1 ± 9.6
P-insulin mIU/La 8.8 (5.0–9.0) 7.0 (5.0–9.0) 9.0 (6.0–12.0)
Diabetes mellitus % yes 0.5 6.3 19.1
Follow-up time yearsa 12.5 (7.79–14.51)
Systolic blood presure mm Hg/yeara 1.56 (0.69–2.63)
Diastolic blood pressure mm Hg/yeara 0.37 (0.00–0.95)
Systolic blood pressure%/yeara 1.27 (0.54–2.24)
Diastolic blood pressure%/yeara 0.78 (0.00–1.21)
Abbreviations are: MPP, Malmo¨ Preventive Project; MDC, Malmo¨ Diet and Cancer; AHT, antihypertensive treatment. All variables except frequency variables are
shown as mean ± SD.
aMedian and interquartile range (IQR).
serum- and glucocorticoid-regulated kinase 1 (SGK-1)
has been shown to be one of the key regulators of ENaC
[10–13]. The SGK-1 gene is located on chromosome 6q23
and is composed of 12 exons spanning 5.5 kb [14]. It
is expressed in virtually all tissues [15], although pre-
dominantly in those of importance for water and elec-
trolyte reabsorption such as renal collecting ducts and
the colonic mucosa [16]. It has been shown that in-
creased SGK-1 phosphorylating activity inhibits the capa-
bility of NEDD4L to down-regulate ENaC [5], thereby
potentially promoting blood pressure elevation. It can
therefore be hypothesized that subjects carrying genetic
SGK-1 variants that makes the protein more sensitive
to stimulation or increases its expression or activity are
prone to get elevated blood pressure. This hypothesis was
recently supported by a study in German twins showing
both linkage and association between the SGK-1 gene
and blood pressure variation [17].
Aldosterone and insulin have been shown to stimulate
SGK-1, primarily by increasing its expression and activ-
ity, respectively [18–22]. Hypertension, in turn, is asso-
ciated with peripheral insulin resistance [23] and fasting
levels of circulating insulin correlate, weakly but consis-
tently, with blood pressure at the population level [24].
As insulin has been shown to be an important stimula-
tor of SGK-1 activity, we hypothesized that the strength
of the direct relationship between fasting insulin concen-
tration and blood pressure at the population level could
be affected by genetically determined differences in ex-
pression, activity, intracellular localization, or sensitivity
of SGK-1 so that genetic SGK-1 variants associated with
higher blood pressure would confer an increased strength
of the insulin-blood pressure relationship.
In the present study, we studied three single nucleotide
polymorphisms (SNPs) in the SGK-1 gene, two of which
have previously been shown to be associated with blood
pressure phenotypes [17] and one located in the promoter
thus potentially affecting SGK-1 expression. The aims of
this study were to test if these three SNPs and a genotype
combination of two of the SNPs, which has previously
been shown to be associated with blood pressure [17] are
associated with blood pressure, blood pressure change
over time and hypertension in a Swedish population.
Additionally, we aimed at investigating whether these
genetic variants also were associated with an increased
strength of the insulin-blood pressure relationship.
METHODS
Subjects
All participants gave written informed consent and the
study was approved by the local ethical committee.
The study population in the present study is a sample
of a cohort study on diet and cancer in Malmo¨, Sweden
[25]. A random 50% (N = 11456) of those who entered
the study between November 1991 and February 1994
were invited to take part in a study of the epidemiology
of carotid artery disease [26]. Of the 5540 subjects who
agreed to participate (participation rate 48.4%) full phe-
notypic data, required for inclusion in the present study
(Table 1), and successfully extracted DNA-samples, was
obtained from 4830 subjects [Malmo¨ Diet and Cancer
(MDC) study]. The study of blood pressure as a continu-
ous variable in MDC was only performed in subjects free
from antihypertensive medication (N = 4001), whereas
the patients on antihypertensive medication (N = 829)
were included when the dichotomized phenotype of “hy-
pertension” and “normotension” was studied in MDC.
Of the subjects not on antihypertensive medication in
MDC we were able to study the blood pressure change
over time in 2171 subjects who previously also had been
investigated in the Malmo¨ Preventive Project (MPP) [27]
with a mean follow-up time from MPP to MDC of 11.2 ±
4.4 years (range 1.0 to 19.3 years). Clinical characteristics
of all subjects free from antihypertensive medication at
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MPP and MDC and those of patients on antihyperten-
sive medication at MDC are shown in Table 1. Of the
829 patients on antihypertensive medication, 37% were
treated with diuretics, 57% with beta blockers, 25% with
calcium antagonists, 16% with drugs blocking the renin-
angiotensin system, and 2% were treated with other types
of antihypertensive medications. Thirty-one percent were
treated with two or more antihypertensive drugs.
Phenotyping
Blood pressure was measured at one occasion, by spe-
cially trained nurses, in the right brachial artery in the
supine position after a 10-minute rest using a mercury
sphygmomanometer. Korotkoff sounds corresponding to
“phase I” was used to define the systolic blood pressure
and “phase V” the diastolic blood pressure.
Blood pressure change over time from MPP to MDC
was expressed as mm Hg increase of blood pressure
per year [(blood pressure at MDC − blood pressure at
MPP)/follow-up time in years]. In order to adjust for
variations in baseline blood pressure at MPP, the blood
pressure change over time was also expressed as per-
cent increase in blood pressure per year [(blood pres-
sure at MDC − blood pressure at MPP)/follow-up time
in years]/blood pressure at MPP × 100.
Hypertension was defined as being on antihypertensive
treatment or having systolic blood pressure or diastolic
blood pressure ≥140/90 mm Hg according to modern di-
agnostic criteria [28] and normotension as having systolic
blood pressure and diastolic blood pressure <140/90 mm
Hg. Uncontrolled hypertension and poorly controlled
hypertension was defined as being on antihypertensive
treatment as well as having systolic blood pressure and di-
astolic blood pressure >140/90 mm Hg and >160/100 mm
Hg, respectively. Body mass index (BMI) was calculated
as the ratio of the weight in kilograms to the square of
the height in meters (kg/m2) measured bare foot in light
clothing. Insulin concentration was measured in plasma,
sampled after overnight fast, at the Department of
Clinical Chemistry, Malmo¨ University Hospital, by a non-
specific radioimmunoassay [26]. Diabetes mellitus was
defined as having a fasting blood glucose concentration
of ≥6.1 mmol/L or being on antidiabetic medication.
SNP selection and genotyping
DNA was extracted from frozen granulocyte or buffy
coat samples using QIAamp-96 spin blood kits (Qiagen,
VWR, West Sussex, UK). Three SNPs in the SGK-1 gene
[dbSNP accession number rs1743964 promotor (C/T),
rs1743966′′ intron 6 (C/T), and rs1057293 exon 8 (C/T)]
were genotyped. SNPs rs1743966 and rs1057293 were se-
lected based upon results from a previous study on blood
pressure variation in German twins [17]. When analyzing
the 4500 bp upstream of the first codon of the SGK-1 gene
using the MatInspector software (Genomatix Software
GmbH, Munich, Germany) the rs1743964 was shown to
be localized in a region harboring a multitude of tran-
scription factor binding sites as well as being the only
SNP within the putative promotor of SGK-1. Accord-
ing to the MatInspector software (Genomatix Software
GmbH) the promotor stretches between 85 to796 bp up-
stream of the first codon. The rs1743964 was thus selected
for genotyping. Genotyping was performed using the
Sequenom Mass ArrayTM system (Sequenom Inc., San
Diego, CA, USA) or by ABI 7900 (Applied Biosystems,
Foster City, CA, USA). An extended genotyping sec-
tion can be found at www.endo.mas.lu.se/html/pub/SGK-
1 primers&manuals.txt. All primers were synthesized
with mass spectrophotometric (MALDI) quality control
(Metabion GmbH, Martinsried, Germany).
Statistics
Data was analyzed with SPSS Statistical Software (ver-
sion 11.5) (SPSS Inc., Chicago, IL, USA). Frequency
differences were analyzed by v 2 test or Fisher’s exact
test where appropriate. Continuous variables are pre-
sented as mean ± standard deviation (SD) if normally
distributed and as median and interquartile range (IQR)
if not. Significance of differences in continuous variables
were tested by t test and analysis of variance (ANOVA)
or Mann-Whitney and Kruskal-Wallis test, depending on
whether the variable was normally distributed or not.
Multiple regression and multiple logistic regression anal-
ysis, respectively, were used to test if genotypic effects on
blood pressure and hypertension were independent of co-
variates. After logarithmic transformation of the change
in blood pressure from MPP to MDC, the general linear
model was used to assess whether the effect of a SGK-1
intron 6 and exon 8 genotype combination on blood pres-
sure change was independent of covariates. Spearman’s
test for correlations was used to calculate correlations.
Fisher’s R to Z transformation was used to test if the
correlation between fasting plasma insulin concentration
and blood pressure was significantly stronger in carriers of
a genotype combination in the SGK-1 gene than in those
who did not carry this combination, using a one-sided
test. All other tests were two-sided and throughout. P <
0.05 was considered statistically significant.
RESULTS
Genotyping success rate and
Hardy-Weinberg equilibrium
In the total material (N = 4830), the genotyping success
rate was 97.3% (N = 4700) for the promotor SNP, 95.9%
(N = 4630) for the intron 6 SNP, and 97.6% (N = 4714)
for the exon 8 SNP. All SNPs were successfully genotyped
in 95.4% (N = 4608) of all subjects. The numbers of sub-
jects in the results section refer to the exact number of
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Table 2. Blood pressure at Malmo¨ Diet and Cancer (MDC) study according to promotor, intron 6 and exon 8 genotypes and a genotype
combination [serum- and glucocorticoid-regulated kinase 1 (SGK-1) risk]
CC CT TT P value
(N = 366) (N = 1552) (N = 1981) CC vs. TT
Promotor C/T polymorphism (N = 3899)
Systolic blood pressure mm Hg 139 ± 17 140 ± 19 139 ± 18 NS
Diastolic blood pressure mm Hg 86 ± 8.7 86 ± 9.3 86 ± 8.8 NS
CC CT TT CT/TT P value
(N = 165) (N = 1180) (N = 2491) (N = 3671) CC vs. CT/TT
Intron C/T polymorphism (N = 3836)
Systolic blood pressure mm Hg 141 ± 18 140 ± 18 139 ± 18 139 ± 18 NS
Diastolic blood pressure mm Hg 87.8 ± 8.5 86.1 ± 9.2 86.0 ± 8.9 86.0 ± 9.0 0.02
CC CT TT CC/CT P value
(N = 3122) (N = 742) (N = 40) (N = 3864) CC/CT vs. TT
Exon 8 C/T polymorphism (N = 3904)
Systolic blood pressure mm Hg 139 ± 18 140 ± 19 134 ± 14 140 ± 18 0.04
Diastolic blood pressure mm Hg 86.1 ± 9.0 86.4 ± 9.1 86.5 ± 8.6 86.1 ± 9.0 NS
SGK-1 risk Other genotype carriers
(N = 128) (N = 3688) P value
Intron 6 CC + exon 8 CC/CT (SGK-1 risk) vs. all other subjects (N = 3816)
Systolic blood pressure mm Hg 143 ± 18 139 ± 18 0.03
Diastolic blood pressure mm Hg 88.2 ± 8.3 86.0 ± 9.0 0.009
Analyses were made on subjects free from antihypertensive medication.
successfully genotyped subjects. Genotype distributions,
in all groups of subjects studied, were in accordance with
Hardy-Weinberg equilibrium. The genotype frequencies
in the total material (N = 4830) were for rs1743964 CC
9.2%, CT 39.6%, and TT 49.6%; rs1743966 CC 4.0%,
CT 30.8%, and TT 65.2%; and rs1057293 CC 80.4%, CT
18.7%, and TT 0.9%.
Variations in the SGK-1 gene and blood pressure at MDC
in subjects without antihypertensive medication
Blood pressure distributions in carriers of various
SGK-1 genotypes without antihypertensive medication
at MDC are depicted in Table 2. Subjects homozygous
for the C allele of the intron 6 polymorphism had sig-
nificantly higher diastolic blood pressure than carriers of
at least one T allele. Carriers of at least one C allele of
the exon 8 polymorphism had significantly higher sys-
tolic blood pressure than subjects homozygous for the T
allele. Subjects simultaneously carrying the intron 6 CC
genotype and the exon 8 CC or CT genotype (SGK-1
risk) had significantly higher systolic blood pressure and
diastolic blood pressure compared to subjects with any
other genotype combination (noncarriers) (Table 2). In
a multiple regression analysis, the effect of the SGK-1
risk on blood pressure was independent of the effects of
age, gender, and BMI for both systolic blood pressure
(P = 0.02) and diastolic blood pressure (P = 0.01). The
promoter variant was not individually nor in any com-
bination associated with any blood pressure phenotype.
The three SNPs studied here were not a associated with
blood pressure variation at MPP (data not shown).
Variations in the SGK-1 gene and blood pressure change
over time from MPP to MDC in subjects without
antihypertensive medication
The change in systolic blood pressure and diastolic
blood pressure from MPP to MDC in subjects without an-
tihypertensive medication, expressed as mm Hg increase
of blood pressure per year and as percent increase in
blood pressure per year, was significantly higher in sub-
jects homozygous for the C allele of the intron 6 poly-
morphism compared to carriers of at least one T allele,
whereas these variables did not differ significantly when
subjects were grouped by genotypes of the promoter or
the exon 8 polymorphisms (Table 3). Both systolic blood
pressure and diastolic blood pressure increased at a sig-
nificantly faster rate from MPP to MDC in carriers of
the SGK-1 risk compared to those who did not carry this
combination, whether expressed as mm Hg increase of
blood pressure per year or as percent increase in blood
pressure per year (Table 3). Furthermore, when applying
the general linear model, the effect of the SGK-1 risk on
change in systolic (P = 0.01) and diastolic (P = 0.006)
blood pressure from MPP to MDC was independent of
age, gender, BMI at MPP, BMI at MDC, follow-up time,
and blood pressure at MPP.
SGK-1 risk and strength of the insulin-blood pressure
correlation at MDC in subjects without antihypertensive
medication
At MDC, carriers of the SGK-1 risk (N = 128) as
compared to noncarriers (N = 3688) had a significantly
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Table 3. Blood pressure change from Malmo¨ Preventive Project (MPP) to Malmo¨ Diet and Cancer (MDC) study according to promotor, intron
6, and exon 8 genotypes and a genotype combination [serum- and glucocorticoid-regulated kinase 1 (SGK-1) risk]
CC CT TT P value
(N = 213) (N = 831) (N = 1074) CC vs. TT
Promotor C/T polymorphism (N = 2118)
Systolic blood pressure mm Hg/year 1.5 (0.6–2.6) 1.6 (0.7–2.7) 1.5 (0.7–2.6) NS
Diastolic blood pressure mm Hg/year 0.3 (0.0–0.9) 0.4 (0.0–1.0) 0.4 (0.0–1.0) NS
Systolic blood pressure %/year 1.3 (0.5–2.5) 1.3 (0.6–2.3) 1.2 (0.5–2.2) NS
Diastolic blood pressure %/year 0.4 (0.0–1.1) 0.5 (0.0–1.2) 0.5 (0.0–1.2) NS
CC CT TT CT/TT P value
(N = 81) (N = 628) (N = 1376) (N = 2004) CC vs. CT/TT
Intron C/T polymorphism (N = 2085)
Systolic blood pressure mm Hg/year 1.9 (1.2–3.3) 1.6 (0.6–2.7) 1.5 (0.7–2.6) 1.5 (0.7–2.6) 0.007
Diastolic blood pressure mm Hg/year 0.7 (0.2–1.2) 0.4 (0.0–0.9) 0.4 (0.0–0.9) 0.4 (0.0–0.9) 0.001
Systolic blood pressure %/year 1.6 (1.0–2.7) 1.3 (0.5–2.3) 1.3 (0.5–2.2) 1.3 (0.5–2.2) 0.007
Diastolic blood pressure %/year 0.8 (0.2–1.6) 0.5 (0.0–1.2) 0.4 (0.0–1.2) 0.4 (0.0–1.2) 0.001
CC CT TT CC/CT P value
(N = 1699) (N = 398) (N = 18) (N = 2097) CC/CT vs. TT
Exon 8 C/T polymorphism (N = 2115)
Systolic blood pressure mm Hg/year 1.6 (0.7–2.6) 1.5 (0.7–2.9) 1.5 (0.8–2.1) 1.6 (0.7–2.6) NS
Diastolic blood pressure mm Hg/year 0.3 (0.0–0.9) 0.4 (0.0–1.1) 0.6 (0.1–0.9) 0.4 (0.0–1.0) NS
Systolic blood pressure %/year 1.3 (0.5–2.2) 1.3 (0.6–2.4) 1.3 (0.6–1.9) 1.3 (0.5–2.2) NS
Diastolic blood pressure %/year 0.4 (0.0–1.2) 0.5 (0.0–1.4) 0.7 (0.1–1.1) 0.4 (0.0–1.2) NS
SGK-1 risk Other genotype carriers
(N = 65) (N = 2005) P value
Intron 6 CC + exon 8 CC/CT (SGK-1 risk) vs. all other subjects (N = 2070)
Systolic blood pressure mm Hg/year 2.1 (1.2–3.4) 1.6 (0.7–2.6) 0.002
Diastolic blood pressure mm Hg/year 0.8 (0.2–1.3) 0.4 (0.0–0.9) 0.001
Systolic blood pressure %/year 1.6 (1.1–2.7) 1.3 (0.5–2.2) 0.002
Diastolic blood pressure %/year 0.9 (0.2–1.7) 0.4 (0.0–1.2) 0.001
Data are given as median (interquartile range) (IQR). Analyses were made on subjects being free from antihypertensive medication.
stronger correlation between fasting insulin concentra-
tion in plasma and diastolic blood pressure (r = 0.32
versus r = 0.17) (P = 0.03). The correlation coefficient
between fasting insulin concentration in plasma and sys-
tolic blood pressure was not significantly higher in carri-
ers of the SGK-1 risk than in noncarriers (r = 0.24 versus
r = 0.17) (NS). In patients treated with anti hypertensive
medication, the difference in the strength of the correla-
tion coefficients between carriers and noncarriers of the
SGK-1 risk was even more pronounced (r = 0.34 versus
r = 0.06) (P = 0.13) for systolic blood pressure and r =
0.41 versus r = 0.12 (P = 0.11) for diastolic blood pres-
sure. However, this difference did not reach significance,
probably due to fact that the number of SGK-1 risk car-
riers on antihypertensive medication was very low (N =
18).
Effect of SGK-1 risk on hypertension
and blood pressure control at MDC
We also analyzed the blood pressure phenotype as a di-
chotomous variable (hypertension and normotension) at
MDC in all subjects successfully genotyped for the SGK-1
risk (N = 4608), thereby allowing inclusion also of sub-
jects on antihypertensive medication who were excluded
Table 4. Proportion of hypertensive patients among carriers and
non-carriers of serum- and glucocorticoid-regulated kinase 1 (SGK-1)
risk (N = 4608)
SGK-1 risk carriers Non-carriers
(N = 146) (N = 4462)
Number of hypertensive 113 (77.4) 2883 (64.6)
patients (%)
Number of normotensive 33 (22.6) 1579 (35.4)
subjects (%)
P = 0.0001
SGK-1 risk, carriers of the CC genotype of the intron 6 polymorphism and the
CT or CC genotype of the exon 8 polymorphism; non carriers, carriers of any
other genotype combination.
in the analyses of blood pressure. The SGK-1 risk was
significantly more common among patients with hyper-
tension than in subjects with normotension (Table 4). In
a multiple logistic regression analysis with hypertension
status (hypertension versus normotension) as dependent
variable and SGK-1 risk status (carriers versus noncarri-
ers), age, gender, and BMI as independent variables, the
odds ratio with 95% confidence intervals (95% CI) for
hypertension in carriers of the SGK-1 risk was 2.0 (95%
CI = 1.3–3.1).
Of the hypertensive patients who were on antihyper-
tensive treatment and had full genotypic information
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(N = 792) 18 patients carried the SGK-1 risk. The pro-
portion SGK-1 risk carriers with uncontrolled hyperten-
sion was 61.1% versus 43.9% in noncarriers (NS) and the
proportion of patients with poorly controlled hyperten-
sion was significantly higher in carriers as compared to
non-carriers of the SGK-1 risk (27.8% versus 8.9%) (P =
0.02). The on-treatment diastolic blood pressure (median,
IQR) was higher in carriers as compared to noncarriers
of the SGK-1 risk (99.0, 89.5–102.5 versus 90.0, 85.098.5)
(P = 0.05), whereas the on-treatment systolic blood pres-
sure did not differ between the two groups (150, 137–170
versus 150, 140–164) (NS).
DISCUSSION
In the present study we found that a combination of two
SNPs in the SGK-1 gene, referred to as the SGK-1 risk,
was associated with elevated blood pressure, increased
progression rate of blood pressure over time, and strength
of the insulin-blood pressure correlation among subjects
free from antihypertensive medication. When including
subjects on antihypertensive medication, we found an as-
sociation between the SGK-1 risk and hypertension and,
finally, among patients on antihypertensive treatment
the SGK-1 risk was associated with poorly controlled
hypertension and higher on-treatment diastolic blood
pressure.
SGK-1 variation and blood pressure
The finding of association between the SGK-1 risk
and increased systolic blood pressure and diastolic blood
pressure in the cross-sectional analysis of untreated sub-
jects is consistent with a previous report where the SGK-1
risk construct was found to mediate a stronger associa-
tion with blood pressure elevation than any of the SNPs
alone [17]. Considering that the previous study was per-
formed in a relatively small set of dizygotic twins and
their parents (N = 232) as well as that false positive asso-
ciations are common in genetic studies of complex traits,
we found it worthwhile to replicate it in a larger mate-
rial of unrelated subjects. In this study we extend and
strengthen the evidence for a role of the SGK-1 risk in
the development of hypertension by showing in a lon-
gitudinal analysis that the SGK-1 risk is associated with
increased blood pressure progression rate over time dur-
ing the clinically highly relevant age span of 47 to 57 years
(Table 1), during which the incidence of hypertension in-
creases dramatically in most populations [29]. The fact
that the effect of the SGK-1 risk on blood pressure pro-
gression over time was independent of the initial blood
pressure (Table 3) suggests that the genetic alteration acts
continuously to increase blood pressure, at least between
the ages of 47 and 57 years.
Selective increases of diastolic blood pressure in in-
tron 6 CC genotype carriers and systolic blood pressure
in carriers of at least one exon 8 C allele are difficult
to explain in terms biologic mechanisms. However, si-
multaneous increases in both systolic blood pressure and
diastolic blood pressure in carriers of SGK-1 risk are in
accordance with the previous study in German twins [17].
Although statistical artefacts cannot be completely ruled
out, the concordance between these two studies provides
strong evidence that the SGK-1 risk truly contributes sig-
nificantly to elevated cross-sectional blood pressure as
well as blood pressure change over time.
In genetic studies of the complex phenotype of blood
pressure, where the genetic effect is expected to be rel-
atively small, adjusting blood pressure for the effects of
antihypertensive treatment is highly error prone. In light
of this, we excluded patients on antihypertensive treat-
ment in the analyses of cross-sectional and longitudinal
blood pressure (Table 1). To enable us to extract genetic
information also from these subjects we performed an
analysis of the dichotomized phenotype of “hyperten-
sion” and “normotension,” using modern guidelines in
the classification [28]. The prevalence of the SGK-1 risk
was significantly higher in the hypertensive than in the
normotensive group (Table 4). The genetic effect was
independent of gender, BMI, and age. Some caution is
warranted when interpreting these results as only the pa-
tients on antihypertensive medication had been clinically
diagnosed with hypertension (Table 1), whereas the ma-
jority fell into the hypertensive category by exceeding the
European Society of Hypertension/European Society of
Cardiology (ESH/ECC) diagnostic blood pressure limits
[28] based on recordings taken at one occasion. When
applying these criteria, the prevalence of hypertension
in our study population was 65%. Similar prevalence of
hypertension (65% to 70%) was found in Europeans in
the corresponding age span in a recent population sur-
vey using the same criteria to define hypertension [29].
However, in both studies a slight overestimation of the
hypertension prevalence is to be expected due to the fact
that the majority of included subjects were not clinically
diagnosed with hypertension but merely exceeded the
upper limit of the ESH/ECC criteria [28].
The discrepancy between invited and attending sub-
jects of the MDC investigation was quite high with a par-
ticipation rate 48.4%. This implies that the material is
not fully representative of the inhabitants of the city of
Malmo¨. It is probable, on the background of the low par-
ticipation rate, that the individuals that participated in
the investigation were healthier, came from higher social
standards, and had a lower load of hazardous environ-
mental factors than the average citizen [30]. However, the
diminution of environmental factors could give genetic
anomalies relatively greater impact on blood pressure el-
evation, thus increasing the power of this study to detect
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an effect of genetic SGK-1 variance. Among patients on
antihypertensive treatment, the carriers of the SGK-1 risk
had higher on-treatment diastolic blood pressure and the
proportion of patients with poorly controlled hyperten-
sion was significantly higher than among noncarriers. This
is interesting as it could imply that SGK-1 risk carriers
respond less well to conventional antihypertensive treat-
ment than noncarriers. Importantly, this study was not
designed to explore the effect of genetic SGK-1 variation
on blood pressure treatment control and, additionally, the
prevalence of SGK-1 risk carriers was very low among
subjects on antihypertensive treatment. Therefore, these
data have to be interpreted cautiously and warrant repli-
cation in studies specifically designed to address this issue.
Studies of monogenic forms of hypertension have
taught us that ENaC plays an important role in the reg-
ulation of renal sodium reabsorption and blood pres-
sure. Furthermore, it has been shown that SGK-1 and
NEDD4L are important regulators of ENaC [31, 32].
Studies on SGK-1 knockout mice [33], the Dahl salt-
sensitive rat [34], and in vitro studies [35] have clearly
indicated that SGK-1 expression is important for re-
nal sodium handling and blood pressure regulation. In
SGK-1 knockout mice, dietary NaCl restriction, as op-
posed to standard NaCl intake, revealed an impaired abil-
ity of the SGK-1 knockout mice to adequately decrease
sodium excretion despite increases in plasma aldosterone
levels as well as decreases in blood pressure and glomeru-
lar filtration rate [33]. In the Dahl salt-sensitive rat the
inability to down-regulate SGK-1 on a high salt diet indi-
cated that the abundance of SGK-1 in the kidney play a
role for the impaired salt adaptation and pathogenesis of
hypertension in the Dahl salt-sensitive rat [34]. These an-
imal studies support our hypothesis that genetically me-
diated increases in expression or activity of SGK-1 could
be an important cause of elevated blood pressure also in
humans. However, the mechanisms by which the SGK-1
risk increases human blood pressure remains to be elu-
cidated. Since none of the two SNPs forming the SGK-1
risk alter the amino acid sequence of the protein, the
most likely explanation is either that the polymorphisms
alters SGK-1 expression or that another nearby variant
or variants, which are in linkage disequilibrium with the
SGK-1 risk genotype combination, alters expression, ac-
tivity, localization, or sensitivity to stimulation of SGK-1.
It should, however, be mentioned that in the absence of
functional in vitro or clinical studies of these and other
polymorphisms in the SGK-1 gene this remains highly
speculative.
Impact of SGK-1 variations on the insulin-blood
pressure relationship
At the population level, insulin and blood pressure are
weakly but consistently correlated with each other [24];
however, the cause of this relationship is unknown. One
potential explanation is that hyperinsulinemia, as a con-
sequence of selective insulin resistance in muscle, fat, and
liver, results in increased insulin-induced sodium reten-
tion in the kidneys [36]. Although expression of SGK-1
in the distal parts of the nephron is strongly induced by
mineralocorticoids [10–13], aldosterone alone, the main
mineralocorticoid in vivo, seems to have only a weak abil-
ity to activate SGK-1. On the other hand, insulin seems to
be an important activator of SGK-1 via its classic signal-
ing pathway through phosphatidylinositol-3 (PI3) kinase,
PDK1 and PDK2 [18–20], suggesting that insulin stim-
ulation of SGK-1 could be an important link between
hyperinsulinemia and elevated blood pressure working
through enhanced ENaC-mediated renal sodium reten-
tion. We therefore hypothesized that the strength of the
direct relationship between circulating fasting insulin and
blood pressure would be greater in carriers of SGK-1
variants associated with higher blood pressure. We found
that carriers of the SGK-1 risk had a stronger correlation
between fasting circulating insulin levels and diastolic
blood pressure than noncarriers, suggesting that insulin
stimulation of SGK-1 results in relatively greater ENaC-
mediated renal sodium reabsorption and greater blood
pressure elevation in SGK-1 risk carriers than in noncar-
riers. One mechanism through which increased SGK-1
activity may prolong the half-life of ENaC in the lu-
minal membrane in the renal tubules is that activated
SGK-1 phosphorylates NEDD4L rendering it incapable
to ubiquitinate and subsequently unable to remove ENaC
from the cell membrane [4, 5]. It can thus be speculated
that the stronger insulin-diastolic blood pressure correla-
tion in SGK-1 risk carriers results from these subjects ei-
ther having enhanced ability of SGK-1 to phosphorylate
NEDD4L, increased SGK-1 sensitivity to insulin stim-
ulation, prolonged half-life of the SGK-1 protein or a
more favorable intracellular position of SGK-1 for phos-
phorylating NEDD4L. However, it should be empha-
sized that the statistical significance of the difference in
correlation coefficient between carriers and noncarriers
of SGK-1 risk is quite weak. Therefore, the finding of
increased insulin-diastolic blood pressure correlation in
SGK-1 risk carriers needs verification in other popula-
tions and further studies are warranted to explain its
molecular mechanism.
CONCLUSION
This study provides confirmation of the previously re-
ported association between the SGK-1 risk and increased
cross-sectional blood pressure, in a large material of unre-
lated Caucasians. Additionally, we show that the SGK-1
risk is associated with increased blood pressure pro-
gression rate, higher prevalence of hypertension, and a
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stronger correlation between fasting plasma insulin con-
centration and diastolic blood pressure. Our data suggest
that SGK-1 risk carriers are at increased risk of hyperten-
sion and that they are more sensitive to the blood pres-
sure elevating effects associated with hyperinsulinemia
implicating that the previously described molecular in-
teraction between insulin, SGK-1, NEDD4L, and ENaC
is of clinical importance. Further support for this hypoth-
esis was obtained from an exploratory analysis showing
that hypertensive patients on pharmacologic treatment,
who carried the SGK-1 risk genotype combination, had
poorer blood pressure control than noncarriers, suggest-
ing that these patients are resistant to conventional an-
tihypertensive treatment. Our results encourage further
studies exploring if SGK-1 risk carriers benefit more from
interventions targeted more specifically at the “insulin,
SGK-1, NEDD4L, and ENaC system” in the preven-
tion and treatment of hypertension. Such interventions
may include amiloride, dietary salt restriction, drugs, and
lifestyle regimens lowering insulin concentration through
improved insulin sensitivity and, in the future, perhaps
selective SGK-1 antagonists and NEDD4L agonists. Fi-
nally, this study highlights the need for a more compre-
hensive genetic analysis of the SGK-1 gene to unravel the
possible functional variants hidden within the gene.
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